Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

H. Tu · SciRah

Researcher profile · Semantic Scholar

H. Tu

Share profile

H. Tu — researcher profile on SciRah

h-index: 37
Works: 209
Citations: 6,198

Most-cited papers

HER2-mediated internalization of cytotoxic agents in ERBB2 amplified or mutant lung cancers
Bob T. Li, Flavia Michelini, S. Misale, E. Cocco +45 more
2020Cancer Discovery241 citations Open access
Semantic Scholar
Longitudinal Undetectable Molecular Residual Disease Defines Potentially Cured Population in Localized Non–Small Cell Lung Cancer
Jia-Tao Zhang, S. Liu, Wei Gao, S. Liu +22 more
2022Cancer Discovery196 citations Open access
Semantic Scholar
Bevacizumab plus erlotinib in Chinese patients with untreated, EGFR-mutated, advanced NSCLC (ARTEMIS-CTONG1509): A multicenter phase 3 study.
Qing Zhou, Chong-Rui Xu, Ying Cheng, Yun-Peng Liu +16 more
2021Cancer Cell171 citations Open access
Semantic Scholar
Overall survival with circulating tumor DNA-guided therapy in advanced non-small-cell lung cancer
J. Jee, E. Lebow, R. Yeh, J. Das +68 more
2022Nature Medicine159 citations Open access
Semantic Scholar
Dynamic circulating tumor DNA during chemoradiotherapy predicts clinical outcomes for locally advanced non-small cell lung cancer patients.
Yi Pan, Jia-Tao Zhang, Xuan Gao, Zhi-Yong Chen +27 more
2023Cancer Cell109 citations Open access
Semantic Scholar
Zongertinib in Previously Treated HER2-Mutant Non-Small-Cell Lung Cancer.
J. Heymach, G. Ruiter, Myung-Ju Ahn, Nicolas Girard +15 more
2025New England Journal of Medicine86 citations
Semantic Scholar
Circulating Tumor DNA-Guided De-Escalation Targeted Therapy for Advanced Non−Small Cell Lung Cancer
S. Dong, Zhen Wang, Jia-Tao Zhang, Bingfa Yan +25 more
2024JAMA Oncology67 citations Open access
Semantic Scholar
Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced non-small cell lung cancer: 2-year follow-up from a randomized, open-label, phase 3 study (CheckMate 078).
Shun Lu, Jie Wang, Ying Cheng, T. Mok +20 more
2020Lung Cancer63 citations Open access
Semantic Scholar
First-line pyrotinib in advanced HER2-mutant non-small-cell lung cancer: a patient-centric phase 2 trial
S. Liu, H. Tu, Xue-Wu Wei, Hong-Hong Yan +26 more
2023Nature Medicine59 citations
Semantic Scholar
MET amplification identified by next-generation sequencing and its clinical relevance for MET inhibitors
Lun-Xi Peng, Guang-Ling Jie, Anna Li, S. Liu +12 more
2021Experimental Hematology & Oncology52 citations Open access
Semantic Scholar
Neoadjuvant nivolumab with or without platinum-doublet chemotherapy based on PD-L1 expression in resectable NSCLC (CTONG1804): a multicenter open-label phase II study
S. Liu, S. Dong, Xue-Ning Yang, R. Liao +18 more
2023Signal Transduction and Targeted Therapy48 citations Open access
Semantic Scholar
Association of genetic and immuno-characteristics with clinical outcomes in patients with RET-rearranged non-small cell lung cancer: a retrospective multicenter study
Chang Lu, Xiao-rong Dong, Jun Zhao, Xu-Chao Zhang +20 more
2020Journal of Hematology & Oncology46 citations Open access
Semantic Scholar
HER2-Selective Tyrosine Kinase Inhibitor, Zongertinib (BI 1810631), in Patients With Advanced/Metastatic Solid Tumors With HER2 Alterations: A Phase Ia Dose-Escalation Study
J. Heymach, F. Opdam, M. Barve, H. Tu +8 more
2025Journal of Clinical Oncology44 citations Open access
Semantic Scholar
Complex ALK Fusions Are Associated With Better Prognosis in Advanced Non-Small Cell Lung Cancer
Jin Kang, Xu-Chao Zhang, Hua-Jun Chen, W. Zhong +13 more
2020Frontiers in Oncology36 citations Open access
Semantic Scholar
Lipid-associated macrophages for osimertinib resistance and leptomeningeal metastases in NSCLC.
Yang-Si Li, W. Lai, Kai Yin, M. Zheng +26 more
2024Cell Reports32 citations Open access
Semantic Scholar
PD-L1 expression guidance on sintilimab versus pembrolizumab with or without platinum-doublet chemotherapy in untreated patients with advanced non-small cell lung cancer (CTONG1901): A phase 2, randomized, controlled trial.
Si-Yang Maggie Liu, Jie Huang, Jia-Yi Deng, Chong-Rui Xu +17 more
2023Science Bulletin32 citations Open access
Semantic Scholar
Clinical outcomes of non-small cell lung cancer patients with leptomeningeal metastases after immune checkpoint inhibitor treatments.
M. Zheng, H. Tu, Jin-Ji Yang, Xu-Chao Zhang +11 more
2021European Journal of Cancer26 citations
Semantic Scholar
Cerebrospinal fluid circulating tumor DNA profiling for risk stratification and matched treatment of central nervous system metastases
M. Zheng, Qing Zhou, Hua-Jun Chen, B. Jiang +26 more
2025Nature Medicine24 citations
Semantic Scholar
Redoxhigh phenotype mediated by KEAP1/STK11/SMARCA4/NRF2 mutations diminishes tissue-resident memory CD8+ T cells and attenuates the efficacy of immunotherapy in lung adenocarcinoma
Xue-Wu Wei, Chang Lu, Yi-Chen Zhang, Xue Fan +16 more
2024Oncoimmunology24 citations Open access
Semantic Scholar
Clinical utility of next-generation sequencing-based ctDNA testing for common and novel ALK fusions
S. Mondaca, E. Lebow, A. Namakydoust, P. Razavi +30 more
2021Lung Cancer22 citations Open access
Semantic Scholar
Expert consensus on treatment for stage III non‐small cell lung cancer
Yi-Long Wu, Shun Lu, Qing-Hua Zhou, Li Zhang +72 more
2023Medicine Advances20 citations Open access
Semantic Scholar
Correlation of distribution characteristics and dynamic changes of gut microbiota with the efficacy of immunotherapy in EGFR-mutated non-small cell lung cancer
Wei-Chi Luo, Shi-Qi Mei, Zi-Jian Huang, Zhi-Hong Chen +18 more
2024Journal of Translational Medicine19 citations Open access
Semantic Scholar
Three-year follow-up and patient-reported outcomes from CheckMate 078: Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced non-small cell lung cancer.
Jian-Hua Chang, Yi-Long Wu, Shun Lu, Jie Wang +25 more
2021Lung Cancer19 citations
Semantic Scholar
First-Line Camrelizumab versus Placebo Plus Chemotherapy with or without Radiotherapy for Brain Metastases in Non-Small-Cell Lung Cancer: The CTONG 2003 Randomized Placebo-Controlled Trial.
Yang-Si Li, Qi-Tao Yu, Q. Bu, Li-Zhu Lin +26 more
2025Journal of Thoracic Oncology17 citations Open access
Semantic Scholar
Clinical outcomes of EGFR +/ METamp+ vs. EGFR +/ METamp‐ untreated patients with advanced non‐small cell lung cancer
K. Peng, Jun-Wei Su, Zhi Xie, Han-Min Wang +12 more
2022Thoracic Cancer17 citations Open access
Semantic Scholar
Association of Cerebrospinal Fluid Tumor DNA Genotyping With Survival Among Patients With Lung Adenocarcinoma and Central Nervous System Metastases
Yang-Si Li, M. Zheng, B. Jiang, H. Tu +3 more
2020JAMA Network Open16 citations Open access
Semantic Scholar
PD-1/PD-L1 combined with LAG3 is associated with clinical activity of immune checkpoint inhibitors in metastatic primary pulmonary lymphoepithelioma-like carcinoma
Y. Zhong, K. Yin, Yu Chen, Zhi Xie +18 more
2022Frontiers in Immunology15 citations Open access
Semantic Scholar
Afatinib in EGFR TKI-Naïve Patients with Locally Advanced or Metastatic EGFR Mutation-Positive Non-Small Cell Lung Cancer: A Pooled Analysis of Three Phase IIIb Studies
A. Passaro, F. de Marinis, H. Tu, K. Laktionov +15 more
2021Frontiers in Oncology15 citations Open access
Semantic Scholar
Circulating tumor cells dynamics during chemotherapy predict survival and response in advanced non-small-cell lung cancer patients
Zhen Wang, Xu-Chao Zhang, W. Feng, Li Zhang +11 more
2023Therapeutic Advances in Medical Oncology14 citations Open access
Semantic Scholar
Allelic context of EGFR C797X mutant lung cancer defines four subtypes with heterogeneous genomic landscape and distinct clinical outcomes.
Chang Lu, Xue-Wu Wei, Zhen Wang, Zhen Zhou +22 more
2023Journal of Thoracic Oncology14 citations Open access
Semantic Scholar
Genetic Profiling of Cell-Free DNA From Pleural Effusion in Advanced Lung Cancer as a Surrogate for Tumor Tissue and Revealed Additional Clinical Actionable Targets.
H. Tu, Yang-Si Li, Xiao-Yan Bai, Yue-Li Sun +17 more
2021Clinical Lung Cancer13 citations
Semantic Scholar
First-Line Zongertinib in Advanced HER2-Mutant Non-Small-Cell Lung Cancer.
J. Heymach, N. Yamamoto, Nicolas Girard, G. Ruiter +20 more
2026New England Journal of Medicine12 citations
Semantic Scholar
Genomic and immune characteristics of HER2‐mutated non‐small‐cell lung cancer and response to immune checkpoint inhibitor‐based therapy
H. Tu, K. Yin, Xiaotian Zhao, E. Ke +18 more
2023Molecular Oncology12 citations Open access
Semantic Scholar
Clinical utility of cerebrospinal fluid-derived circular RNAs in lung adenocarcinoma patients with brain metastases
Zhen Wang, R. Yu, Xiaoxi Chen, H. Bao +8 more
2022Journal of Translational Medicine12 citations Open access
Semantic Scholar
T lymphocytes expressing the switchable chimeric Fc receptor CD64 exhibit augmented persistence and antitumor activity.
Yuanbin Cui, Tingjie Yuan, Ying Wang, Diwei Zheng +20 more
2025Cell Reports11 citations Open access
Semantic Scholar
Monitoring of Circulating Tumor DNA and Indication of De-Escalation Adjuvant Targeted Therapy for EGFR-Mutated NSCLC After Complete Resection
S. Dong, Bingfa Yan, S. Liu, Xuan Gao +14 more
2024JTO Clinical and Research Reports11 citations
Semantic Scholar
Phase Ia/Ib trial of zongertinib (BI 1810631), a HER2-specific tyrosine kinase inhibitor (TKI), in patients (pts) with HER2 aberration-positive solid tumors: Updated Phase Ia data from Beamion LUNG-1, including progression-free survival (PFS) data.
J. Heymach, F. Opdam, M. Barve, H. Tu +7 more
2024Journal of Clinical Oncology11 citations Open access
Semantic Scholar
Subsequent treatments beyond progression on osimertinib in EGFR-mutated NSCLC and leptomeningeal metastases
M. Zheng, Yang-Si Li, H. Tu, Hao Sun +10 more
2022BMC Medicine11 citations Open access
Semantic Scholar
A phase II trial of anlotinib plus EGFR-TKIs in advanced non-small cell lung cancer with gradual, oligo, or potential progression after EGFR-TKIs treatment (CTONG-1803/ALTER-L001)
Hua-Jun Chen, H. Tu, Yanping Hu, Yun Fan +14 more
2025Journal of Hematology & Oncology10 citations Open access
Semantic Scholar
Phase I Beamion Lung 1 trial of BI 1810631, a HER2 tyrosine kinase inhibitor (TKI), as monotherapy in patients (pts) with advanced/metastatic solid tumors with HER2 aberrations: Updated data.
J. Heymach, F. Opdam, M. Barve, H. Tu +7 more
2023Journal of Clinical Oncology10 citations
Semantic Scholar
Sintilimab versus pembrolizumab in monotherapy or combination with chemotherapy as first-line therapy for advanced non–small cell lung cancer: Results from phase 2, randomized clinical trial (CTONG1901).
S. Liu, Qing Zhou, Hong-Hong Yan, Gan Bin +7 more
2022Journal of Clinical Oncology10 citations
Semantic Scholar
Advancing Global Health Equity in Oncology Clinical Trial Access.
T. Adewole, Bjorn Albrecht, S. Beg, Otis Brawley +97 more
2024Cancer Discovery9 citations
Semantic Scholar
Uncommon/rare oncogenic drivers in non‐small cell lung cancer: Consensus and contention
Yi-Long Wu, Shun Lu, Ying Cheng, Qing Zhou +71 more
2023Medicine Advances9 citations Open access
Semantic Scholar
A Phase IIIb Open-Label, Single-Arm Study of Afatinib in EGFR TKI-Naïve Patients with EGFRm+ NSCLC: Final Analysis, with a Focus on Patients Enrolled at Sites in China
H. Tu, Ji-Feng Feng, M. Shi, Jun Zhao +25 more
2022Targeted oncology9 citations Open access
Semantic Scholar
Longitudinal Plasma Proteomics-Derived Biomarkers Predict Response to MET Inhibitors for MET-Dysregulated NSCLC
Guang-Ling Jie, Lun-Xi Peng, M. Zheng, Hao Sun +11 more
2023Cancers8 citations Open access
Semantic Scholar
T lymphocytes expressing the switchable chimeric Fc receptor CD64 exhibit augmented persistence and antitumor activity.
Yuanbin Cui, Tingjie Yuan, Ying Wang, Diwei Zheng +20 more
2023Cell Reports8 citations Open access
Semantic Scholar
Follow-up Analysis Enhances Understanding of Molecular Residual Disease in Localized Non–Small Cell Lung Cancer
Jia-Tao Zhang, S. Liu, Xuan Gao, S. Liu +15 more
2025Clinical Cancer Research7 citations Open access
Semantic Scholar
FLAIR: A Phase II, Open Label, Randomized Study of Osimertinib Plus Bevacizumab Versus Osimertinib in Recurrent or Metastatic Treatment-Naïve NSCLC Patients Harboring EGFR 21L858R Mutation.
Qing Zhou, Jie Li, S. Cang, Jia-Xing Lin +10 more
2024Clinical Lung Cancer7 citations Open access
Semantic Scholar
Biomarker-Driven Studies With Multi-targets and Multi-drugs by Next-Generation Sequencing for Patients With Non-Small-Cell Lung Cancer: An Open-Label, Multi-center, Phase II Adaptive Umbrella Trial and a Real-World Observational Study (CTONG1702&CTONG1705).
S. Liu, Hong-Hong Yan, Xue-Wu Wei, Chang Lu +14 more
2022Clinical Lung Cancer7 citations Open access
Semantic Scholar
P49.01 Drug Holiday Based on Minimal Residual Disease Status After Local Therapy Following EGFR-TKI Treatment for Patients With Advanced NSCLC
S. Dong, Z. Wang, Q. Zhou, L. Yang +11 more
2021Journal of Thoracic Oncology7 citations Open access
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

Jin-Ji Yang×28
Invite
Jin-Ji Yang — researcher profile on SciRah
Xu-Chao Zhang×24
Invite
Xu-Chao Zhang — researcher profile on SciRah
S. Liu×20
Invite
S. Liu — researcher profile on SciRah
Qing Zhou×19
Invite
Qing Zhou — researcher profile on SciRah

×17

Invite

Chong-Rui Xu — researcher profile on SciRah

Hong-Hong Yan×15

Invite

Hong-Hong Yan — researcher profile on SciRah

Invite

Yi-Long Wu — researcher profile on SciRah

Invite

Yi-Long Wu — researcher profile on SciRah

Hua-Jun Chen×13

Invite

Hua-Jun Chen — researcher profile on SciRah

Invite

Zhen Wang — researcher profile on SciRah

Xue-Ning Yang×11

Invite

Xue-Ning Yang — researcher profile on SciRah

Invite

Yang-Si Li — researcher profile on SciRah